Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 262 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... March 24, 2021 No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... September 9, 2021 Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Load more HOT NEWS Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... Working Mom with Stage II Breast Cancer Receives Custom Wig Made... Investigating suspected prostate cancer: improving GP-patient communication
